Early Initiation of Anti-Amyloid Therapies Is Key To Alzheimer’s Care

Anti-amyloid therapies, specifically monoclonal antibodies likelecanemab and donanemab, represent a historic shift in Alzheimer’s disease (AD) care, moving from symptomatic management to biological disease modification. Growing evidence from pivotal trials demonstrates that removing amyloid plaques from the brain can significantly slow cognitive and functional decline. However, these treatments work most effectively when initiated during the early symptomatic stages, such as Mild Cognitive Impairment (MCI) or mild dementia.

A Biological Turning Point

This shift toward earlier intervention is critical because AD is a progressive condition where toxic biological changes begin years before memory loss becomes obvious. The timing of treatment initiation doesn’t just affect efficacy. The quick timing tied to earlier intervention fundamentally dictates the safety monitoring protocols, the cost-benefit ratio for the patient, and the complex ethical conversations clinicians must navigate regarding long-term risks.

Why It Matters

Reshaping the Care Paradigm

The introduction of these therapies has transformed AD from a traditionally untreatable age-related decline into a biologically defined disorder with modifiable trajectories. By intervening while the brain still possesses substantial functional capacity, clinicians aim to preserve independence for a longer duration.

1. From Sequential to Biologically Anchored Diagnosis

In the new therapeutic era, diagnostic pathways are shifting from a sequential, observation-based model to a biologically anchored, time-sensitive workflow. Real-world implementation at centers like CARD in Milan utilizes a fast-track model to ensure patients don’t miss the narrow therapeutic window. This involves:

• Telemedicine Triage: Remote screening to identify eligible candidates early and exclude major contraindications like anticoagulant use.
• Biomarker Anchoring: Using plasma biomarkers (like pTau-217) and Cerebrospinal Fluid (CSF) analysis to confirm the presence of amyloid pathology before symptoms advance.

2. Safety and the ARIA Challenge

The most significant safety concern with anti-amyloid therapy isAmyloid-Related Imaging Abnormalities (ARIA), which include brain edema (ARIA-E) and microhemorrhages (ARIA-H).

• Monitoring Burdens: Traditional trial protocols required frequent, rigid MRI schedules that are difficult to replicate in routine practice due to limited resource availability and patient anxiety.
• Risk-Adapted Surveillance: A more pragmatic, real-world approach is emerging where monitoring is tailored to the patient’s genetic risk. For example, ApoE-epsilon-4 carriers, who face a higher risk of ARIA, require intensified MRI schedules, while non-carriers may be monitored with fewer routine scans.

3. Policy and Economic Realities

The out-of-pocket nature of these treatments in many regions (until full reimbursement pathways are established) adds a layer of complexity. In the Italian experience, patients often bear the direct costs of the medication through named-patient importation programs, deciding to start early, a significant financial as well as medical choice.

Who It Affects

A Multi-Stakeholder Shift

The transition to disease-modifying therapy impacts every level of the healthcare ecosystem.

Patients and Families: Managing Expectations

For patients, particularly young-onset individuals in their 50s and 60s who are still professionally active, early therapy offers hope for maintaining autonomy. However, clinicians must carefully reframe these expectations:

• Realistic Goals: The focus must be on disease slowing rather than the recovery of lost functions or a “cure”.
• The Burden of Choice: Patients must weigh the modest slowing of decline against the logistical rigors of bi-weekly or monthly infusions and repeated MRI scans.

Clinicians: The Multidisciplinary Mandate

The management of these therapies extends far beyond a single neurologist. A dedicated fast-track program requires a coordinated team of:

• Neurologists and Neuropsychologists for cognitive staging and shared decision-making.
• Neuroradiologists to interpret complex MRI findings and distinguish treatment-related ARIA from spontaneous cerebral amyloid angiopathy (CAA).
• Clinical Coordinators to manage infusion schedules and emergency 24/7 triage for ARIA-related symptoms.

Payers and Systems: Resource Allocation

Health systems face a sudden demand for high-volume diagnostic tools. This includes increased needs for Amyloid PET imaging and infusion chairs, as well as the specialized workforce required to manage potential side effects.

What Changes

New Clinical Protocols

The San Raffaele Model outlines a five-step assessment process that defines the new standard of care :

Practical Considerations for Treatment Initiation

Clinicians must look beyond rigid global cognitive scores (like a fixed MMSE cutoff) when deciding on eligibility.

1. Cognitive-Functional Discordance

Real-world data shows that global scales often fail to capture a patient’s true potential to benefit. Some patients with lower MMSE scores may still maintain high levels of independence and should not be automatically excluded if their functional assessment remains strong.

2. Genetic Risk and Titration

The ApoE -epsilon-4-genotype is a major determinant of safety. Recent protocols, such as the TRAILBLAZER-ALZ 6 regimen, utilize a slower dose-escalation (titration) to markedly reduce ARIA risk without losing the drug’s biological efficacy. This genotype-informed titration is now becoming a standard safety pillar in European centers.

3. Emerging Atypical Phenotypes

While clinical trials focused on typical memory-loss patterns, real-world practice is seeing more atypical AD variants, such as primary progressive aphasia or posterior cortical atrophy. These younger patients often have high motivation for treatment and a biological rationale supporting efficacy, even if they were underrepresented in the original studies.

TRAILBLAZER-ALZ 6 Key insights

TRAILBLAZER-ALZ 6 presents the 76-week results of a clinical trial (NCT05738486) aimed at reducing treatment-related side effects.

Core Objective

The study investigated whether alternative dosing regimens fordonanemab could reduce the frequency and severity of Amyloid-Related Imaging Abnormalities with edema/effusions (ARIA-E) without compromising the drug’s ability to clear amyloid plaques in patients with early symptomatic Alzheimer’s disease (AD).

Key Findings

The Modified Titration arm was the only experimental regimen that successfully met the study’s primary objective.

Significant Risk Reduction: Modified titration resulted in a 34.6% relative risk reduction (RRR) in ARIA-E frequency compared with the standard-dosing arm through 76 weeks.

Lower Severity: Radiographic severity of ARIA-E was significantly lower in the modified titration group (p=0.015).

Safety Profile:

- - ARIA-E Frequency: 15.6% in the modified titration arm vs. 24.2% in the standard arm. - Symptomatic ARIA-E: Numerically lower in the modified titration group (2.8%) compared to standard dosing (4.8%). - Serious Adverse Events (SAEs): Comparable across both groups (23.1% modified vs. 24.6% standard). - Pharmacodynamic Efficacy: The modified titration maintained comparable amyloid reduction to the standard arm (70.9 Centiloids vs. 72.1 Centiloids at 76 weeks).

Dosing Comparison

The study compared four distinct regimens:

1. Standard Arm: 700 mg for the first 3 doses, then 1400 mg every 4 weeks.
2. Modified Titration: Once-monthly dosing increasing gradually: 350 mg, 700 mg, 1050 mg, then 1400 mg thereafter.
3. Dose Skipping: A regimen designed to allow for “vascular healing”.
4. Cmax: An alternative regimen based on drug concentration hypotheses.

Biomarker Response

Despite the slower initial dosing in the modified titration arm, long-term biological effects were nearly identical by week 76:

• Amyloid Clearance: 82.8% of modified titration participants reached the amyloid-clearance threshold (<24.1 Centiloids) compared to 80.5% in the standard arm.
• Tau and Inflammation: Reductions in plasma P-tau217 and GFAP (a marker of glial activity) were similar across both treatment arms.

TRAILBLAZER-ALZ 6 Conclusion

The authors conclude that a more gradual titration of donanemab significantly lowers the risk and severity of ARIA-E. Because most ARIA-E events occur within the first six months of treatment, the initial lower dosage in the modified arm may reduce inflammation and vascular permeability during the crucial early phase of amyloid mobilization.

Unresolved Questions and the Path Forward

As these therapies move from the lab to the frontline, several open research areas remain:

• Stopping Rules: Should treatment stop once the brain is clear of amyloid (the “treat-to-clear” model)? Current evidence suggests amyloid re-accumulates very slowly, appearing at a rate of only 2–3 Centiloids per year after stopping, which may allow for intermittent re-treatment.
• The TRAC Framework: The new Treatment-Related Amyloid Clearance (TRAC) framework aims to categorize patients by how much amyloid they clear, but it is not yet fully validated to guide switching or discontinuation decisions in daily practice.
• Therapeutic Switching: For patients who don’t clear enough amyloid on one drug (e.g., lecanemab), switching to another (e.g., donanemab) after a “washout” period is becoming a feasible real-world strategy.

Conclusion: A Multi-Dimensional Transformation

The successful implementation of anti-amyloid therapies depends on more than just pharmacology. It requires a coordinated care model supported by real-world registries. The transformation of Alzheimer’s care must integrate:

1. Biological Redefinition: Shifting from symptoms to biomarkers.
2. Adaptive Risk Governance: Moving from fixed trial protocols to individualized safety monitoring.
3. Organizational Redesign: Integrating specialized tertiary centers with local shared-care networks to ensure safety close to the patient’s home.

By prioritizing accurate diagnosis, transparent communication, and equitable resource allocation, health systems can translate this scientific breakthrough into a resilient, patient-centered model of dementia care.